Rapid vascular regrowth in tumors after reversal of VEGF inhibition

Journal of Clinical Investigation

Volumn 116, Issue 10, 2006, Pages 2610-2621

  Mancuso, Michael R ^a   Davis, Rachel ^a   Norberg, Scott M ^a   O'Brien, Shaun ^a   Sennino, Barbara ^a   Nakahara, Tsutomu ^a   Yao, Virginia J ^a   Inai, Tetsuichiro ^a,f   Brooks, Peter ^b   Freimark, Bruce ^c,g   Shalinsky, David R ^d   Hu Lowe, Dana D ^d   McDonald, Donald M ^a,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c Cell Matrix Inc   (United States)

^d PFIZER INC   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f KYUSHU UNIVERSITY   (Japan)

^g Peregrine Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AG 028262; ALPHA SMOOTH MUSCLE ACTIN; AXITINIB; COLLAGEN TYPE 4; HUIV26 ANTIBODY; MATRIX METALLOPROTEINASE; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN C; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANIMAL TISSUE; ARTICLE; BASEMENT MEMBRANE; CONTROLLED STUDY; DRUG INHIBITION; ENDOTHELIUM CELL; IMMUNOFLUORESCENCE TEST; IMMUNOREACTIVITY; LEWIS CARCINOMA; MOUSE; NONHUMAN; PERICYTE; PHENOTYPE; PRIORITY JOURNAL; REVASCULARIZATION; TUMOR GROWTH; VASCULAR PATENCY;

ACTINS; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD31; BASEMENT MEMBRANE; BLOOD VESSELS; CARCINOMA, LEWIS LUNG; COLLAGEN TYPE IV; ENDOTHELIUM, VASCULAR; IMIDAZOLES; INDAZOLES; INSULINOMA; MATRIX METALLOPROTEINASES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; ORGANIC CHEMICALS; PERICYTES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 33749441325     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI24612     Document Type: Article

References (65)

1. Hurwitz, H., et al. 2004. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350:2335-2342.
2. Wedam, S.B., et al. 2006. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J. Clin. Oncol. 24:769-777.
3. Nieder, C., Wiedenmann, N., Andratschke, N., and Molls, M. 2006. Current status of angiogenesis inhibitors combined with radiation therapy. Cancer Treat Rev. 32:348-364.
4. Jain, R.K. 2001. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med. 7:987-989.
5. Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E., and Hanahan, D. 2003. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 111:1287-1295. doi:10.1172/JCI200317929.
6. Inai, T., et al. 2004. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am. J. Pathol. 165:35-52.
7. Jain, R.K. 2005. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 307:58-62.
8. Kim, K.J., et al. 1993. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 362:841-844.
9. Witte, L., et al. 1998. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an antiangiogenic therapeutic strategy. Cancer Metastasis Rev. 17:155-161.
10. Im, S.A., et al. 1999. Antiangiogenesis treatment for gliomas: transfer of antisense-vascular endothelial growth factor inhibits tumor growth in vivo. Cancer Res. 59:895-900.
11. Goldman, C.K., et al. 1998. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc. Natl. Acad. Sci. U. S. A. 95:8795-8800.
12. Davidoff, A.M., Leary, M.A., Ng, C.Y., and Vanin, E.F. 2001. Gene therapy-mediated expression by tumor cells of the angiogenesis inhibitor flk-1 results in inhibition of neuroblastoma growth in vivo. J. Pediatr. Surg. 36:30-36.
13. Holash, J., et al. 2002. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl. Acad. Sci. U. S. A. 99:11393-11398.
14. Millauer, B., Shawver, L.K., Plate, K.H., Risau, W., and Ullrich, A. 1994. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature. 367:576-579.
15. Fong, T.A., et al. 1999. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 59:99-106.
16. Laird, A.D., et al. 2000. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res. 60:4152-4160.
17. Drevs, J., et al. 2002. PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res. 62:4015-4022.
18. Hu-Lowe, D., et al. 2002. Characterization of potency and activity of the VEGF/PDGF receptor tyrosine kinase inhibitor AG013736. Proc. Am. Assoc. Cancer Res. 43:A5357.
19. Baffert, F., et al. 2006. Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. Am. J. Physiol. Heart Circ. Physiol. 290:H547-H559.
20. Kamba, T., et al. 2006. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am. J. Physiol. Heart Circ. Physiol. 290:H560-H576.
21. Fox, W.D., et al. 2002. Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer. Clin. Cancer Res. 8:3226-3231.
22. Vracko, R., and Benditt, E.P. 1972. Basal lamina: the scaffold for orderly cell replacement. Observations on regeneration of injured skeletal muscle fibers and capillaries. J. Cell Biol. 55:406-419.
23. Hall, S. 1997. Axonal regeneration through acellular muscle grafts. J. Anat. 190:57-71.
24. Fournier, A.E., and Strittmatter, S.M. 2002. Regenerating nerves follow the road more traveled. Nat. Neurosci. 5:821-822.
25. Kalluri, R. 2003. Basement membranes: structure, assembly and role in tumour angiogenesis. Nat. Rev. Cancer. 3:422-433.
26. Baffert, F., et al. 2004. Age-related changes in vascular endothelial growth factor dependency and angiopoietin-1-induced plasticity of adult blood vessels. Circ. Res. 94:984-992.
27. Wickman, G., et al. 2003. Further characterization of the potent VEGF/PDGF receptor tyrosine kinase inhibitor, AG-013736, in preclinical tumor models for its antiangiogenesis and antitumor activity. Proc. Am. Assoc. Cancer Res. 44:A3780.
28. Zou, H.Y., et al. 2004. AG-028262, a novel selective VEGFR tyrosine kinase antagonist that potently inhibits KDR signaling and angiogenesis in vitro and in vivo. Proc. Am. Assoc. Cancer Res. 45:A2578.
29. Shalinsky, D.R., et al. 1999. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann. N. Y. Acad. Sci. 878:236-270.
30. Xu, J., et al. 2001. Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J. Cell Biol. 154:1069-1079.
31. Hangai, M., et al. 2002. Matrix metalloproteinase-9-dependent exposure of a cryptic migratory control site in collagen is required before retinal angiogenesis. Am. J. Pathol. 161:1429-1437.
32. Roth, J.M., et al. 2006. Inhibition of experimental metastasis by targeting the HUIV26 cryptic epitope in collagen. Am. J. Pathol. 168:1576-1586.
33. Hashizume, H., et al. 2000. Openings between defective endothelial cells explain tumor vessel leakiness. Am. J. Pathol. 156:1363-1380.
34. Morikawa, S., et al. 2002. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am. J. Pathol. 160:985-1000.
35. Baluk, P., Morikawa, S., Haskell, A., Mancuso, M., and McDonald, D.M. 2003. Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am. J. Pathol. 163:1801-1815.
36. Huang, J., et al. 2003. Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc. Natl. Acad. Sci. U. S. A. 100:7785-7790.
37. Zhang, W., Ran, S., Sambade, M., Huang, X., and Thorpe, P.E. 2002. A monoclonal antibody that blocks VEGF binding to VEGFR2 (KDR/Flk-1) inhibits vascular expression of Flk-1 and tumor growth in an orthotopic human breast cancer model. Angiogenesis. 5:35-44.
38. Uemura, A., et al. 2002. Recombinant angiopoietin-1 restores higher-order architecture of growing blood vessels in mice in the absence of mural cells. J. Clin. Invest. 110:1619-1628. doi:10.1172/JCI200215621.
39. Bergers, G., et al. 2000. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2:737-744.
40. Inoue, M., Hager, J.H., Ferrara, N., Gerber, H.P., and Hanahan, D. 2002. VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell. 1:193-202.
41. Gerhardt, H., et al. 2003. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J. Cell Biol. 161:1163-1177.
42. Verbeek, M.M., Otte-Holler, I., Wesseling, P., Ruiter, D.J., and de Waal, R.M. 1994. Induction of alpha-smooth muscle actin expression in cultured human brain pericytes by transforming growth factor-beta 1. Am. J. Pathol. 144:372-382.
43. Mariani, T.J., Arikan, M.C., and Pierce, R.A. 1999. Fibroblast tropoelastin and alpha-smooth-muscle actin expression are repressed by particulate-activated macrophage-derived tumor necrosis factoralpha in experimental silicosis. Am. J. Respir. Cell Mol. Biol. 21:185-192.
44. Sund, M., Xie, L., and Kalluri, R. 2004. The contribution of vascular basement membranes and extracellular matrix to the mechanics of tumor angiogenesis. APMIS. 112:450-462.
45. Folkman, J. 2004. Endogenous angiogenesis inhibitors. APMIS. 112:496-507.
46. Price, A., et al. 1999. Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340. Clin. Cancer Res. 5:845-854.
47. Nguyen, Q.T., Sanes, J.R., and Lichtman, J.W. 2002. Pre-existing pathways promote precise projection patterns. Nat. Neurosci. 5:861-867.
48. Ide, C., Tohyama, K., Yokota, R., Nitatori, T., and Onodera, S. 1983. Schwann cell basal lamina and nerve regeneration. Brain Res. 288:61-75.
49. Gulati, A.K. 1996. Peripheral nerve regeneration through short- and long-term degenerated nerve transplants. Brain Res. 742:265-270.
50. Fugleholm, K., Sorensen, J., Schmalbruch, H., and Krarup, C. 1998. Axonal elongation through acellular nerve segments of the cat tibial nerve: importance of the near-nerve environment. Brain Res. 792:309-318.
51. Ochi, M., Wakasa, M., Ikuta, Y., and Kwong, W.H. 1994. Nerve regeneration in predegenerated basal lamina graft: the effect of duration of predegeneration on axonal extension. Exp. Neurol. 128:216-225.
52. Houck, K.A., Leung, D.W., Rowland, A.M., Winer, J., and Ferrara, N. 1992. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J. Biol. Chem. 267:26031-26037.
53. Poltorak, Z., et al. 1997. VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix. J. Biol. Chem. 272:7151-7158.
54. Jeon, H., et al. 1996. Pericytes from microvessel fragment produce type IV collagen and multiple laminin isoforms. Biosci. Biotechnol. Biochem. 60:856-861.
55. Nehls, V., Denzer, K., and Drenckhahn, D. 1992. Pericyte involvement in capillary sprouting during angiogenesis in situ. Cell Tissue Res. 270:469-474.
56. Beck, L., Jr., and D'Amore, P.A. 1997. Vascular development: cellular and molecular regulation. FASEB J. 11:365-373.
57. Benjamin, L.E., Hemo, I., and Keshet, E. 1998. A plasticity window for blood vessel remodeling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development. 125:1591-1598.
58. Nicosia, R.F., and Villaschi, S. 1995. Rat aortic smooth muscle cells become pericytes during angiogenesis in vitro. Lab. Invest. 73:658-666.
59. Lyden, D., et al. 2001. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. 7:1194-1201.
60. Kopp, H.G., Ramos, C.A., and Rafii, S. 2006. Contribution of endothelial progenitors and proangiogenic hematopoietic cells to vascularization of tumor and ischemic tissue. Curr. Opin. Hematol. 13:175-181.
61. Li, H., Gerald, W.L., and Benezra, R. 2004. Utilization of bone marrow-derived endothelial cell precursors in spontaneous prostate tumors varies with tumor grade. Cancer Res. 64:6137-6143.
62. Rajantie, I., et al. 2004. Adult bone marrow-derived cells recruited during angiogenesis comprise precursors for periendothelial vascular mural cells. Blood. 104:2084-2086.
63. Casanovas, O., Hicklin, D.J., Bergers, G., and Hanahan, D. 2005. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell. 8:299-309.
64. De Palma, M., et al. 2005. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell. 8:211-226.
65. Hanahan, D. 1985. Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature. 315:115-122.